Logo image of IVF

INVO FERTILITY INC (IVF) Stock Fundamental Analysis

NASDAQ:IVF - Nasdaq - US44984F6097 - Common Stock - Currency: USD

1.84  +0.02 (+1.1%)

After market: 1.79 -0.05 (-2.72%)

Fundamental Rating

2

IVF gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 187 industry peers in the Health Care Equipment & Supplies industry. IVF may be in some trouble as it scores bad on both profitability and health. IVF is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year IVF has reported negative net income.
IVF had a negative operating cash flow in the past year.
In the past 5 years IVF always reported negative net income.
In the past 5 years IVF always reported negative operating cash flow.
IVF Yearly Net Income VS EBIT VS OCF VS FCFIVF Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2M -4M -6M -8M -10M

1.2 Ratios

IVF has a Return On Assets of -79.24%. This is in the lower half of the industry: IVF underperforms 77.01% of its industry peers.
Looking at the Return On Equity, with a value of -343.90%, IVF is doing worse than 84.49% of the companies in the same industry.
Industry RankSector Rank
ROA -79.24%
ROE -343.9%
ROIC N/A
ROA(3y)-109.72%
ROA(5y)-93.78%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IVF Yearly ROA, ROE, ROICIVF Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K

1.3 Margins

IVF's Gross Margin of 41.57% is on the low side compared to the rest of the industry. IVF is outperformed by 66.31% of its industry peers.
IVF's Gross Margin has declined in the last couple of years.
IVF does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 41.57%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-23.07%
GM growth 5Y-13.44%
IVF Yearly Profit, Operating, Gross MarginsIVF Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K

More info and screens

1

2. Health

2.1 Basic Checks

IVF does not have a ROIC to compare to the WACC, probably because it is not profitable.
IVF has more shares outstanding than it did 1 year ago.
The number of shares outstanding for IVF has been increased compared to 5 years ago.
The debt/assets ratio for IVF is higher compared to a year ago.
IVF Yearly Shares OutstandingIVF Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200K 400K 600K
IVF Yearly Total Debt VS Total AssetsIVF Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

IVF has an Altman-Z score of -5.09. This is a bad value and indicates that IVF is not financially healthy and even has some risk of bankruptcy.
IVF has a Altman-Z score of -5.09. This is in the lower half of the industry: IVF underperforms 70.59% of its industry peers.
A Debt/Equity ratio of 0.27 indicates that IVF is not too dependend on debt financing.
IVF has a Debt to Equity ratio (0.27) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF N/A
Altman-Z -5.09
ROIC/WACCN/A
WACC5.75%
IVF Yearly LT Debt VS Equity VS FCFIVF Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M 15M 20M

2.3 Liquidity

A Current Ratio of 0.08 indicates that IVF may have some problems paying its short term obligations.
With a Current ratio value of 0.08, IVF is not doing good in the industry: 97.86% of the companies in the same industry are doing better.
A Quick Ratio of 0.07 indicates that IVF may have some problems paying its short term obligations.
With a Quick ratio value of 0.07, IVF is not doing good in the industry: 97.86% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.08
Quick Ratio 0.07
IVF Yearly Current Assets VS Current LiabilitesIVF Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

7

3. Growth

3.1 Past

IVF shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -309.11%.
The Revenue has grown by 55.20% in the past year. This is a very strong growth!
The Revenue has been growing by 34.57% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-309.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1856.02%
Revenue 1Y (TTM)55.2%
Revenue growth 3Y16.23%
Revenue growth 5Y34.57%
Sales Q2Q%3.86%

3.2 Future

The Earnings Per Share is expected to grow by 23.45% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 81.28% on average over the next years. This is a very strong growth
EPS Next Y92.84%
EPS Next 2Y39.17%
EPS Next 3Y23.45%
EPS Next 5YN/A
Revenue Next Year10.02%
Revenue Next 2Y10.01%
Revenue Next 3Y10%
Revenue Next 5Y81.28%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IVF Yearly Revenue VS EstimatesIVF Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M
IVF Yearly EPS VS EstimatesIVF Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 -50 -100 -150 -200

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

IVF reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IVF. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IVF Price Earnings VS Forward Price EarningsIVF Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IVF Per share dataIVF EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20

4.3 Compensation for Growth

IVF's earnings are expected to grow with 23.45% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.17%
EPS Next 3Y23.45%

More info and screens

0

5. Dividend

5.1 Amount

IVF does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INVO FERTILITY INC

NASDAQ:IVF (8/1/2025, 8:00:02 PM)

After market: 1.79 -0.05 (-2.72%)

1.84

+0.02 (+1.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-20 2025-05-20
Earnings (Next)08-12 2025-08-12
Inst Owners5.28%
Inst Owner ChangeN/A
Ins Owners0.36%
Ins Owner ChangeN/A
Market Cap1.71M
Analysts80
Price TargetN/A
Short Float %N/A
Short Ratio0.07
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)118.75%
Min Revenue beat(2)0.94%
Max Revenue beat(2)236.57%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.26
P/FCF N/A
P/OCF N/A
P/B 0.23
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-23.21
EYN/A
EPS(NY)-0.99
Fwd EYN/A
FCF(TTM)-6.89
FCFYN/A
OCF(TTM)-6.73
OCFYN/A
SpS7.09
BVpS7.86
TBVpS-20.94
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -79.24%
ROE -343.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 41.57%
FCFM N/A
ROA(3y)-109.72%
ROA(5y)-93.78%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-23.07%
GM growth 5Y-13.44%
F-Score3
Asset Turnover0.21
Health
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 16.04%
Cap/Sales 2.26%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.08
Quick Ratio 0.07
Altman-Z -5.09
F-Score3
WACC5.75%
ROIC/WACCN/A
Cap/Depr(3y)84.61%
Cap/Depr(5y)530.77%
Cap/Sales(3y)6.25%
Cap/Sales(5y)7.65%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-309.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1856.02%
EPS Next Y92.84%
EPS Next 2Y39.17%
EPS Next 3Y23.45%
EPS Next 5YN/A
Revenue 1Y (TTM)55.2%
Revenue growth 3Y16.23%
Revenue growth 5Y34.57%
Sales Q2Q%3.86%
Revenue Next Year10.02%
Revenue Next 2Y10.01%
Revenue Next 3Y10%
Revenue Next 5Y81.28%
EBIT growth 1Y-68.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-13.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-10.39%
OCF growth 3YN/A
OCF growth 5YN/A